<DOC>
	<DOC>NCT00776555</DOC>
	<brief_summary>The purpose of this study is to compare subjective drug liking using the Drug Rating Questionnaire, subject version (DRQ-S), question 2 and pharmacokinetics of Vyvanse™ and ADDERALL XR® when administered as an oral solution. Hypothesis: DRQ-S, question 2 will show no difference between the two drugs</brief_summary>
	<brief_title>Compare Subjective Drug Liking &amp; Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution</brief_title>
	<detailed_description>Not required</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<mesh_term>Dextroamphetamine</mesh_term>
	<mesh_term>Adderall</mesh_term>
	<criteria>Inclusion Criteria Healthy young adults, male or female (nonpregnant and nonlactating), age 1825 years at time of consent Have a body mass index (BMI) between 20.0 and 29.0kg/m2 Satisfactory medical assessment with no clinically significant or relevant Subject must demonstrate a positive response to amphetamine at Screening Exclusion Criteria A history of current or recurrent disease that could have an effect on the study Subject has a history of seizures, any tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder Subject has a concurrent chronic or acute illness or other condition that might confound the results of safety assessments or that might increase risk to the subject Subject has any clinically significant ECG and/or laboratory abnormalities Subject has a documented allergy, hypersensitivity or intolerance to amphetamines Subject has been prescribed or has taken amphetamine products in the past, including childhood; recreational use may not be exclusionary per the Investigator's discretion Subject has a known family history of sudden cardiac death or ventricular arrhythmia Subject has a recent history (within the past 6 months) of suspected substance abuse or dependence disorder (excluding nicotine) Subject has participated in any investigational clinical or vaccine trial within 30 days prior to the first dose of study drug Subjects is currently considered a suicide risk, has previously made a suicide attempt or has a prior history of, or is currently demonstrating suicidal ideation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Not required</keyword>
</DOC>